🇺🇸 FDA
Pipeline program

Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.

EudraCT: 2008-004014-27

Phase 2 other completed

Quick answer

Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. for Graft Versus Host Disease is a Phase 2 program (other) at Design Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Design Therapeutics
Indication
Graft Versus Host Disease
Phase
Phase 2
Modality
other
Status
completed

Clinical trials